Evidence map›Paper›PMID 24792830›Full record

ArticlePharmaceutical research2014

Handling missing data in a duloxetine population pharmacokinetic/pharmacodynamic model - imputation methods and selection models.

Eunice Yuen, Ivelina Gueorguieva, Leon Aarons

Abstract read
PubMed Publisher
In one paragraph

Article in Pharmaceutical research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Eunice YuenGlobal PK/PD and Pharmacometrics, Eli Lilly and Co., Erl Wood Manor, Windlesham Surrey, GU20 6PH, UK, yuenes@lilly.com.
Ivelina Gueorguieva
Leon Aarons

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeIn pharmacokinetic (PK)/pharmacodynamic (PD) modelling and simulations (M&S), omitting dropouts can cause inaccuracies in parameter estimation and clinical trial simulations (CTS). This study examines the impact of different imputation methods for missing data on the interpretation of model results, as well as develops a selection model (where dropout and efficacy are jointly modelled) for use in CTS.

methodsMissing data were imputed using single and multiple imputation and pattern mixtures methods for a previously reported duloxetine PK/PD model. The probability of dropout was described in the selection model and CTS was conducted with a hypothetical drug to examine the impact of dropout on trial results.

resultsThe study completion rate was 75% and dropouts were not random. Model parameters obtained with different imputation methods were mostly within 40% (range 0 to 63%) compared to the model without dropouts. CTS showed 0.3 points lower median pain scores and 3% lower coefficient of variation over the 12-week simulations when dropout was included.

conclusionsMissing data had little impact on the original population PK/PD analyses. Sensitivity analyses for dropouts should be conducted in M&S exercises. The utility of selection models in CTS was explored via a hypothetical case study.

Indexed as

Models, BiologicalPatient DropoutsAnalgesicsComputer SimulationData Interpretation, StatisticalDose-Response Relationship, DrugDuloxetine HydrochlorideHumansNonlinear DynamicsPainPain MeasurementProbabilityRandomized Controlled Trials as TopicThiophenesAnalgesicsDuloxetine HydrochlorideThiophenes

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.